Physician profile
Michael A Schwartz
NPI 1972591683
$30,825.20
in general payments reported to CMS, 2019-2025
94 companies · $6,704 in 2025
The $6,704 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,452 · 2020: $3,347 · 2021: $3,431 · 2022: $3,267 · 2023: $4,408 · 2024: $5,216 · 2025: $6,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,218.27 |
| Education | $110.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,558.84 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Celgene Corporation | $2,054.98 | 2019-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,790.96 | 2019-2025 | |
| Pfizer INC. | $1,737.27 | 2019-2025 | |
| Janssen Biotech, INC. | $1,696.72 | 2019-2025 | Erleada, Darzalex, Carvykti |
| Merck Sharp & Dohme LLC | $1,518.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $1,359.30 | 2019-2025 | Polivy, Lunsumio, Phesgo |
| Incyte Corporation | $1,181.16 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $1,179.26 | 2020-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $955.09 | 2019-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $857.65 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Genzyme Corporation | $744.99 | 2019-2025 | |
| Abbvie INC. | $735.80 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $715.79 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $619.24 | 2019-2023 | Padcev, Tukysa, Adcetris |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $548.83 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $496.78 | 2019-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $461.89 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $440.11 | 2019-2025 | Trodelvy |
| Amgen INC. | $427.34 | 2019-2023 | Lumakras, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $402.47 | 2019-2025 | Libtayo |
| Exelixis INC. | $373.41 | 2019-2025 | Cabometyx |
| Eisai INC. | $369.93 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $369.65 | 2023-2025 | Orgovyx |
| Lilly USA, LLC | $311.25 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacosmos Therapeutics INC. | $309.96 | 2023-2025 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $296.24 | 2021-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $289.43 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Deciphera Pharmaceuticals INC. | $279.65 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Servier Pharmaceuticals LLC | $249.68 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $247.90 | 2019-2025 | Xarelto |
| Emd Serono, INC. | $236.98 | 2020-2025 | Bavencio |
| Kite Pharma, INC. | $223.26 | 2020-2024 | Yescarta |
| Taiho Oncology, INC. | $217.91 | 2020-2025 | |
| Adaptive Biotechnologies Corporation | $206.44 | 2022-2025 | Clonoseq |
| Stemline Therapeutics INC. | $191.35 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $191.14 | 2024-2025 | Ogsiveo, Gomekli |
| Beigene USA, INC. | $181.99 | 2021-2025 | Brukinsa, Tevimbra |
| Sobi, INC | $181.27 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $180.90 | 2021-2024 | Myrisk |
| Epizyme, INC. | $180.68 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.58 | 2019-2025 | |
| Beone Medicines USA, INC. | $163.02 | 2025 | Brukinsa, Tevimbra |
| Mirati Therapeutics, INC. | $160.55 | 2023-2024 | Krazati |
| Clovis Oncology, INC. | $155.83 | 2019-2021 | |
| Tersera Therapeutics LLC | $154.34 | 2020-2025 | Zoladex |
| Tempus Ai, INC | $154.09 | 2024-2025 | Xt Cdx |
| Myovant Sciences INC. | $138.18 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $135.73 | 2019-2025 | Onivyde |
| Eusa Pharma (US) LLC | $124.15 | 2019-2020 | |
| Blueprint Medicines Corporation | $117.75 | 2023-2025 | Ayvakit |
| Kyowa Kirin, INC. | $113.08 | 2020-2022 | |
| Foundation Medicine, INC. | $111.31 | 2019-2021 | |
| Morphosys, US INC. | $109.55 | 2022-2024 | Monjuvi |
| Karyopharm Therapeutics INC. | $102.57 | 2020-2025 | Xpovio |
| Intuitive Surgical, INC. | $93.69 | 2025 | |
| Alexion Pharmaceuticals, INC. | $84.41 | 2021-2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $80.59 | 2024-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $76.88 | 2023-2025 | Zepzelca |
| Dova Pharmaceuticals | $76.04 | 2020-2021 | |
| Adc Therapeutics America, INC. | $75.90 | 2022-2023 | |
| Tesaro, INC. | $61.92 | 2019 | |
| G1 Therapeutics, INC. | $59.82 | 2022-2023 | Cosela |
| Helsinn Therapeutics (U.S.), INC. | $54.75 | 2019 | |
| Acceleron Pharma, INC. | $54.59 | 2021 | |
| Verastem, INC. | $52.29 | 2019-2020 | |
| Cti Biopharma Corp. | $52.26 | 2023 | Vonjo |
| Puma Biotechnology, INC. | $50.04 | 2022-2025 | |
| Genmab U.S., INC. | $44.39 | 2024-2025 | Epkinly |
| Legend Biotech USA INC. | $35.18 | 2025 | Carvykti |
| Teva Pharmaceuticals USA, INC. | $34.10 | 2019 | |
| Janssen Scientific Affairs, LLC | $33.41 | 2019 | |
| Ge Healthcare | $24.14 | 2025 | |
| Amag Pharmaceuticals, INC. | $23.36 | 2019 | |
| Syndax Pharmaceuticals, INC. | $22.98 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.73 | 2025 | |
| Pharmaand Gmbh | $21.83 | 2025 | Rubraca |
| Sun Pharmaceutical Industries INC. | $21.74 | 2019 | |
| Iovance Biotherapeutics, INC. | $20.86 | 2025 | Amtagvi |
| Invivyd INC | $19.33 | 2025 | Pemgarda |
| Fennec Pharmaceuticals, INC. | $17.32 | 2024 | Pedmark |
| Abbott Laboratories | $16.49 | 2025 | Infinity |
| Apellis Pharmaceuticals, INC. | $15.05 | 2024 | Empaveli |
| Aurobindo Pharma USA, INC. | $14.90 | 2019 | |
| Geron Corporation | $14.82 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $14.38 | 2024 | Sylvant |
| Tolmar, INC. | $14.26 | 2025 | Rubraca |
| Advanced Accelerator Applications | $14.24 | 2019 | |
| Shire North American Group INC | $13.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.24 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Reblozyl $1,127Enhertu $1,104Kisqali $562Orgovyx $507Keytruda $472Jakafi $452Erleada $436Tukysa $387Darzalex $373Ojjaara $364Sarclisa $334Venclexta $325Pluvicto $315Libtayo $303Adcetris $298Xtandi $296Carvykti $293Monjuvi $280Elrexfio $278Trodelvy $277Padcev $271Braftovi $247Tecvayli $246Opdivo $244Monoferric $239Ibrance $235Mektovi $230Talzenna $221Imfinzi $221Lynparza $207Calquence $202Qinlock $198Orserdu $191Inlyta $191Elahere $185Piqray $177Brukinsa $177Lorbrena $175Ogsiveo $172Bosulif $168Tavalisse $163Rezlidhia $163Krazati $161Fabhalta $159Xt Cdx $154Clonoseq $153Iclusig $145Tevimbra $141Pemazyre $141Tibsovo $137Xospata $135Doptelet $130Inqovi $127Lonsurf $127Verzenio $127Jaypirca $127Lutathera $125Scemblix $121Bavencio $119Ayvakit $118Imbruvica $115Xofigo $114Nubeqa $114Alunbrig $114Yescarta $112Jemperli $111Cosela $111Cabometyx $111Myrisk $109Welireg $109Polivy $107Vonjo $104Lenvima $103Zejula $96.28Zoladex $95.48Da Vinci Surgical System $93.69Talvey $93.48Xalkori $92.71Injectafer $90.66Ninlaro $85.38Fotivda $84.87Epkinly $83.04Romvimza $78.80Zepzelca $76.88Zynyz $72.18Cablivi $71.73Rybrevant $67.26Idhifa $67.01Retevmo $67.00Lunsumio $64.80Gavreto $62.61Phesgo $62.44Pyrukynd $57.84Blenrep $55.34Enjaymo $53.91Onivyde $53.23Paxlovid $50.25Besponsa $48.30Keytruda Qlex $45.61Datroway $42.50
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.